Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

VARIZIG 125 UNIT

VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) : 125 UNIT · DIN 02442183 · KI BIOPHARMA LLC

Health Canada status: MARKETED

What is VARIZIG?

VARIZIG 125 UNIT contains VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) : 125 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02442183, held by KI BIOPHARMA LLC, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 11-Jul-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is VARIZIG used for?

Prevention or reduction in severity of maternal infections within 4 days of exposure to the varicella zoster virus.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02442183
Brand nameVARIZIG
Generic / active ingredientVARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) : 125 UNIT
ManufacturerKI BIOPHARMA LLC
Strength125 UNIT
Dosage formSOLUTION
Route of administrationINTRAVENOUS ; INTRAMUSCULAR
ScheduleSchedule D
ATC codeJ06BB03 VARICELLA/ZOSTER IMMUNOGLOBULIN
AHFS class80:04.00
BiosimilarNo
Health Canada statusMARKETED
Status date11-Jul-2022
Original market date2015-08-14 00:00:00

How is it administered?

Dose based on weight: 125 IU/10 kg up to max 625 IU. Administer IV (over 3-5 mins) or IM within 96 hours of exposure. Minimum dose 125 IU. Max dose 625 IU for patients >40 kg.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at 2-8°C. Do not freeze. Do not use after expiration date.

How is it supplied?

Single-use vial containing a minimum potency of 125 IU in 1.2 mL. Available in 125 IU/vial.

Contraindications

Known immunity to varicella zoster virus; IgA deficiency; history of anaphylactic or severe systemic reaction to immune globulins; hypersensitivity to any ingredient or container component.

Warnings and precautions

Prepared from human plasma (risk of infectious agents). Monitor for 20 mins post-admin. Risk of rare thrombotic events, TRALI, and hypersensitivity/anaphylaxis. Contains trace IgA.

What can be used instead?

Other Canadian products sharing ATC code J06BB03 VARICELLA/ZOSTER IMMUNOGLOBULIN. 1 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
VARICELLA ZOSTER IMMUNE GLOBULIN INJ125 UNIT / 2.5 MLLIQUIDMASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABORATORIESCANCELLED POST MARKETDIN 00554286
VARICELLA-ZOSTER IMMUNE GLOBULIN (HUMAN)100 UNITLIQUIDMASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABORATORIESCANCELLED POST MARKETDIN 02231277
VARIZIG125 UNITKITCANGENE CORPORATION A SUBSIDIARY OF EMERGENT BIOSOLUTIONS INC.CANCELLED POST MARKETDIN 02243342

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for VARIZIG

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for VARIZIG

Health Canada Drug Product Database (DPD), DIN 02442183. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.